Bank of New York Mellon Corp Takes Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Bank of New York Mellon Corp bought a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 454,464 shares of the company's stock, valued at approximately $1,018,000. Bank of New York Mellon Corp owned approximately 0.24% of Taysha Gene Therapies at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TSHA. China Universal Asset Management Co. Ltd. boosted its holdings in Taysha Gene Therapies by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company's stock worth $103,000 after acquiring an additional 14,286 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Taysha Gene Therapies during the 4th quarter valued at about $28,000. Dynamic Technology Lab Private Ltd bought a new stake in Taysha Gene Therapies during the 4th quarter valued at about $31,000. Chicago Partners Investment Group LLC raised its holdings in Taysha Gene Therapies by 21.4% in the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company's stock worth $239,000 after buying an additional 23,740 shares during the last quarter. Finally, Cannon Global Investment Management LLC bought a new position in shares of Taysha Gene Therapies in the first quarter worth approximately $69,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock traded down $0.04 during trading hours on Friday, reaching $2.15. 5,460,949 shares of the stock traded hands, compared to its average volume of 2,350,190. The company has a 50 day moving average price of $2.20 and a 200 day moving average price of $2.59. Taysha Gene Therapies, Inc. has a one year low of $1.27 and a one year high of $4.32. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $440.62 million, a price-to-earnings ratio of -4.39 and a beta of 0.41.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The business had revenue of $1.11 million during the quarter, compared to analysts' expectations of $3.62 million. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. During the same period in the prior year, the company earned ($0.38) earnings per share. On average, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Piper Sandler decreased their price objective on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an "overweight" rating for the company in a report on Monday, July 1st. Needham & Company LLC decreased their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Monday, August 12th. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Chardan Capital reiterated a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Finally, BMO Capital Markets initiated coverage on shares of Taysha Gene Therapies in a research note on Thursday, June 27th. They set an "outperform" rating and a $5.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has an average rating of "Buy" and a consensus target price of $6.38.

Insider Buying and Selling

In related news, major shareholder Paul B. Manning acquired 1,333,333 shares of the stock in a transaction dated Thursday, June 27th. The shares were purchased at an average cost of $2.25 per share, with a total value of $2,999,999.25. Following the transaction, the insider now directly owns 1,333,333 shares in the company, valued at $2,999,999.25. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.70% of the stock is owned by insiders.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.